Figure 5.
Increased in vivo antitumor activity of candidate oncolytic VACV with combination of gene deletions rescuing IRF3 activation
(A–D) 5 × 105 tumor cells were subcutaneously implanted at day −9 on the flank of 6- to 8-week-old BALB/c mice (Renca tumors, A and B) or C57BL/6 mice (B16 tumors, C and D), and viruses were intratumorally administered at days 0 and 4 at a dose of 1 × 107 PFU/injection. PBS-injected mice served as controls. For monitoring tumor growth, the tumors were measured two to three times per week until termination criteria were reached. Tumor volume (A and C) and overall survival (B and D) are plotted for 7–9 mice/group ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.